0.2993
price down icon2.00%   -0.0061
pre-market  プレマーケット:  .31   0.0107   +3.58%
loading
前日終値:
$0.3054
開ける:
$0.32
24時間の取引高:
1.06M
Relative Volume:
0.34
時価総額:
$29.39M
収益:
$147.75M
当期純損益:
$-284.23M
株価収益率:
-0.1022
EPS:
-2.93
ネットキャッシュフロー:
$-317.54M
1週間 パフォーマンス:
+2.78%
1か月 パフォーマンス:
+7.97%
6か月 パフォーマンス:
-9.90%
1年 パフォーマンス:
-75.26%
1日の値動き範囲:
Value
$0.291
$0.32
1週間の範囲:
Value
$0.291
$0.339
52週間の値動き範囲:
Value
$0.18
$1.53

Fibrogen Inc Stock (FGEN) Company Profile

Name
名前
Fibrogen Inc
Name
セクター
Healthcare (1148)
Name
電話
415-978-1200
Name
住所
350 BAY STREET, SAN FRANCISCO, CA
Name
職員
225
Name
Twitter
@FibroGenInc
Name
次回の収益日
2025-03-17
Name
最新のSEC提出書
Name
FGEN's Discussions on Twitter

FGEN を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
FGEN
Fibrogen Inc
0.2993 29.39M 147.75M -284.23M -317.54M -2.93
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
432.00 115.57B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
574.16 60.30B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
542.47 37.56B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
266.86 35.18B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ONC
Beigene Ltd Adr
224.73 26.10B 3.81B -644.79M -669.77M -6.24

Fibrogen Inc Stock (FGEN) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2023-08-08 ダウングレード BofA Securities Neutral → Underperform
2023-06-26 ダウングレード BofA Securities Buy → Neutral
2023-06-26 ダウングレード Raymond James Outperform → Mkt Perform
2023-06-26 ダウングレード Stifel Buy → Hold
2023-06-26 ダウングレード William Blair Outperform → Mkt Perform
2023-06-02 アップグレード Stifel Hold → Buy
2023-01-31 アップグレード William Blair Mkt Perform → Outperform
2023-01-26 アップグレード Raymond James Mkt Perform → Outperform
2023-01-05 アップグレード BofA Securities Neutral → Buy
2021-09-22 ダウングレード Goldman Neutral → Sell
2021-08-20 アップグレード Raymond James Underperform → Mkt Perform
2021-07-16 ダウングレード BofA Securities Buy → Neutral
2021-07-16 ダウングレード Stifel Buy → Hold
2021-04-07 ダウングレード H.C. Wainwright Buy → Neutral
2021-04-07 ダウングレード Mizuho Buy → Neutral
2021-03-31 アップグレード BofA Securities Neutral → Buy
2021-03-02 ダウングレード Jefferies Buy → Hold
2021-02-01 開始されました H.C. Wainwright Buy
2020-10-26 開始されました Raymond James Underperform
2020-07-10 再開されました Stifel Buy
2020-05-01 開始されました Cowen Market Perform
2020-04-27 開始されました BofA/Merrill Neutral
2019-05-29 再開されました Goldman Neutral
2019-05-10 ダウングレード William Blair Outperform → Mkt Perform
2019-04-12 開始されました Piper Jaffray Neutral
2019-02-11 再開されました Stifel Buy
2018-12-19 アップグレード Citigroup Neutral → Buy
2017-08-08 繰り返されました Leerink Partners Outperform
2017-08-08 繰り返されました Stifel Buy
2017-07-21 ダウングレード Goldman Buy → Neutral
2017-07-11 開始されました Jefferies Buy
2016-02-11 アップグレード Credit Suisse Neutral → Outperform
2016-01-21 開始されました Credit Suisse Neutral
2015-12-04 開始されました Citigroup Buy
2015-09-23 開始されました Lake Street Hold
2015-07-29 開始されました Citigroup Buy
2015-07-20 アップグレード Goldman Neutral → Buy
2014-12-09 開始されました Stifel Buy
すべてを表示

Fibrogen Inc (FGEN) 最新ニュース

pulisher
May 13, 2025

FibroGen (FGEN) Receives Reaffirmed Buy Rating from HC Wainwrigh - GuruFocus

May 13, 2025
pulisher
May 13, 2025

FibroGen, Inc. (NASDAQ:FGEN) Q1 2025 Earnings Call Transcript - Insider Monkey

May 13, 2025
pulisher
May 13, 2025

FibroGen outlines $185M China divestiture and extended cash runway into 2027 while advancing prostate cancer pipeline - MSN

May 13, 2025
pulisher
May 13, 2025

FibroGen Inc (FGEN) Q1 2025 Earnings Call Highlights: Strategic Moves and Cost Management Amid ... - Yahoo Finance

May 13, 2025
pulisher
May 13, 2025

FibroGen Inc earnings beat by $0.15, revenue fell short of estimates - Investing.com Nigeria

May 13, 2025
pulisher
May 13, 2025

FibroGen Reports Q1 2025 Earnings and Strategic Updates - TipRanks

May 13, 2025
pulisher
May 12, 2025

FibroGen (FGEN) Boosts Sale Proceeds from Chinese Division - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Earnings call transcript: FibroGen Q1 2025 sees revenue drop, stock rises - Investing.com Canada

May 12, 2025
pulisher
May 12, 2025

FibroGen Q1 2025 Earnings Call Transcript - MarketBeat

May 12, 2025
pulisher
May 12, 2025

FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance

May 12, 2025
pulisher
May 12, 2025

FibroGen Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 12, 2025
pulisher
May 12, 2025

FibroGen Inc Reports Q1 2025 Earnings: Revenue Surpasses Estimat - GuruFocus

May 12, 2025
pulisher
May 12, 2025

FibroGen: Q1 Earnings Snapshot - San Antonio Express-News

May 12, 2025
pulisher
May 12, 2025

FIBROGEN INC SEC 10-Q Report - TradingView

May 12, 2025
pulisher
May 12, 2025

FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

May 12, 2025
pulisher
May 10, 2025

FibroGen (FGEN) Set to Release Q1 Earnings Results - GuruFocus

May 10, 2025
pulisher
May 05, 2025

FibroGen to Report First Quarter 2025 Financial Results - GlobeNewswire

May 05, 2025
pulisher
May 05, 2025

FibroGen Q1 2025 Earnings Call: Key Details for May 12 Financial Results Release - Stock Titan

May 05, 2025
pulisher
May 05, 2025

FibroGen, Inc. to Announce Q1 2025 Financial Results and Host Conference Call on May 12 - Nasdaq

May 05, 2025
pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 27, 2025

Investor Network: FibroGen, Inc. to Host Earnings Call - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 11, 2025

FGEN Stock Price and Chart — NASDAQ:FGEN - TradingView

Apr 11, 2025
pulisher
Apr 08, 2025

Investors Don't See Light At End Of FibroGen, Inc.'s (NASDAQ:FGEN) Tunnel And Push Stock Down 26% - simplywall.st

Apr 08, 2025
pulisher
Apr 03, 2025

FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times

Apr 03, 2025
pulisher
Apr 01, 2025

William Blair Keeps Their Hold Rating on FibroGen (FGEN) - The Globe and Mail

Apr 01, 2025
pulisher
Mar 30, 2025

FibroGen extends merger option deadline with Fortis - Investing.com Australia

Mar 30, 2025
pulisher
Mar 28, 2025

FibroGen extends merger option deadline with Fortis By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

Morgan Stanley’s Adam Jonas Is Pounding the Table on This 1 ‘Unique’ Stock - The Globe and Mail

Mar 28, 2025
pulisher
Mar 28, 2025

FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology - The Manila Times

Mar 28, 2025
pulisher
Mar 28, 2025

FibroGen reports promising FG-3246 study results for prostate cancer - Investing.com

Mar 28, 2025
pulisher
Mar 27, 2025

1 Top Cryptocurrency to Buy Before It Soars 14,623%, According to Michael Saylor - The Globe and Mail

Mar 27, 2025
pulisher
Mar 25, 2025

Fibrogen CEO Wettig Thane buys $50,663 in common stock By Investing.com - Investing.com Australia

Mar 25, 2025
pulisher
Mar 25, 2025

Fibrogen CEO Wettig Thane buys $50,663 in common stock - Investing.com India

Mar 25, 2025
pulisher
Mar 24, 2025

Fibrogen director James Schoeneck buys $105,040 in stock By Investing.com - Investing.com Canada

Mar 24, 2025
pulisher
Mar 24, 2025

Fibrogen director James Schoeneck buys $105,040 in stock - Investing.com

Mar 24, 2025
pulisher
Mar 20, 2025

In the Red? AstraZeneca Acquires FibroGen, Inc.’s China Subsidiary - Law Street Media

Mar 20, 2025
pulisher
Mar 19, 2025

FibroGen, Inc. (NASDAQ:FGEN) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 19, 2025

Fibrogen Inc (FGEN) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Fibrogen Inc (FGEN) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Schoeneck James A
Director
Mar 20 '25
Buy
0.35
250,000
88,000
323,722
Schoeneck James A
Director
Mar 21 '25
Buy
0.34
50,000
17,040
373,722
Adib Deyaa
Chief Medical Officer
Jun 12 '24
Buy
1.17
22,123
25,884
82,123
$65.71
price down icon 3.01%
$19.31
price down icon 3.11%
$32.82
price down icon 1.59%
$24.61
price down icon 2.57%
$94.50
price down icon 2.85%
biotechnology ONC
$224.73
price down icon 3.65%
大文字化:     |  ボリューム (24 時間):